0000899243-18-024192.txt : 20180911 0000899243-18-024192.hdr.sgml : 20180911 20180911163627 ACCESSION NUMBER: 0000899243-18-024192 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180907 FILED AS OF DATE: 20180911 DATE AS OF CHANGE: 20180911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FISHMAN ROBERT S CENTRAL INDEX KEY: 0001232237 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 181065191 MAIL ADDRESS: STREET 1: 2071 STIERLIN COURT CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-09-07 0 0001088856 CORCEPT THERAPEUTICS INC CORT 0001232237 FISHMAN ROBERT S C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 0 1 0 0 Chief Medical Officer Common Stock 2018-09-07 4 M 0 8000 3.51 A 8000 D Common Stock 2018-09-07 4 S 0 8000 14.5666 D 0 D Stock Option (Right to Buy) 3.51 2018-09-07 4 M 0 8000 0.00 D 2025-09-29 Common Stock 8000 345000 D These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $14.22 to $14.81 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. /s/ G. Charles Robb, Attorney-in-Fact for Robert S. Fishman 2018-09-11